Eu­ro­pean reg­u­la­tor says ev­i­dence shows no thy­roid can­cer link to GLP-1s

Cur­rent ev­i­dence doesn’t sup­port a link be­tween GLP-1 re­cep­tor ag­o­nists and thy­roid can­cer, Eu­rope’s drug reg­u­la­tor an­nounced Fri­day fol­low­ing safe­ty con­cerns that have been raised for the pop­u­lar weight loss and di­a­betes drugs.

The Eu­ro­pean Med­i­cines Agency flagged a thy­roid can­cer safe­ty sig­nal ear­li­er this year over a 2022 study sug­gest­ing a po­ten­tial in­creased risk in pa­tients with type 2 di­a­betes. Af­ter re­view­ing da­ta from pub­li­ca­tions, ob­ser­va­tion­al stud­ies and drug­mak­ers (in­clud­ing clin­i­cal and post-mar­ket­ing da­ta), the EMA’s safe­ty com­mit­tee has de­ter­mined that “no up­dates to the prod­uct in­for­ma­tion are war­rant­ed based on the avail­able da­ta.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER